Ischemix is a privately-held, clinical-stage pharmaceutical company developing a portfolio of novel cytoprotective compounds for the prevention and treatment of serious diseases and conditions, including cardiac, renal and neurological. Cytoprotective compounds have broad potential therapeutic utility in multiple organ systems and disease states. The Company’s lead product candidate, CMX-2043, is a patented, new chemical entity based on a naturally-occurring compound.
Ischemix has previously released positive data from SUPPORT-1, a 140-patient Phase 2a of CMX-2043, which demonstrated the ability of the compound to reduce the rise in biomarkers of cell death to a statistically significant degree in subjects undergoing PCI. Ischemix is currently enrolling subjects in a 240-patient CARIN trail to study the ability of CMX-2043 to reduce the incidence of contrast-induced acute kidney injury (“CI-AKI”) and peri-procedural MI in patients entering the cardiac catheterization lab. The Company is also engaged in studying the use of CMX-2043 and other compounds for additional indications.